Mar. 13 at 5:24 PM
$MDNAF It’s hard to know who is selling, or why there is such a lack of support for a company who continues to present best in class data.
As a long term shareholder, it’s equally hard to watch. Unfortunately, there simply isn’t much to do but wait for Dr. Merchant to find a suitor / partner, or raise more money to pursue their latest goals for 2026:
- Complete patient enrollment in ABILITY-1 study in MDNA11 monotherapy and combination arms across prioritized indications ( cutaneous melanoma, endometrial cancer, MSI-H/dMMR and MSS/TMB-H cancers) including any new expansion cohorts (for eg, CRC and NSCLC) with a focus on 2L/3L in post–anti-PD1 settings
- Report updated clinical data from MDNA11 monotherapy and combination expansion cohorts including 2L/3L and last-line anti-PD1–treated patients enrolled within the ABILITY-1 study
- Share interim clinical data from the Phase 1/2 study of MDNA11 in neoadjuvant melanoma trial (NEO-CYT) throughout 2026